VivoSim Labs, INC. - What You Need to Know (Updated)

Thinking about investing in VivoSim Labs? It is exciting to get in on the ground floor, but before you commit your hard-earned money, let’s look at what the company does and the risks involved.

Here is a friend-to-friend guide to the VivoSim Labs offering.

1. What does this company actually do?

Think of VivoSim Labs as architects of "digital biology." They build 3D human tissue models—specifically liver and intestinal organoids—that act as a testing ground for new drugs. Instead of relying on animal testing, which often fails to predict human reactions, pharmaceutical companies use VivoSim’s platform to see how a drug affects human cells. It is like a flight simulator for medicine, designed to save clients time and money.

2. How do they make money and are they growing?

They earn money through service contracts, providing testing and data analysis to large pharmaceutical and biotech companies. However, the company is in a fragile financial position. They have lost over $350 million since they started. They currently lose money every month, and their cash will only last until July 2026. Because of this, their auditors have expressed "substantial doubt" about the company’s ability to stay in business.

3. What is this specific offering?

This is a "best efforts" offering, meaning there is no guarantee the company will raise the full amount they want.

• The Bundle: For every share you buy at $1.14, you receive 1.5 warrants. These give you the right to buy more shares later at a set price.
• The Catch: These warrants have a "cashless exercise" feature. If the stock price is higher than the exercise price, the company issues new shares to warrant holders without receiving any cash. This creates more shares, which reduces your ownership percentage and shrinks your "slice of the pie."
• The Uncertainty: The company hopes to raise $3.3 million. However, management has "broad discretion" over how to spend it. They have not set aside money for specific projects, meaning they may use it for general expenses or legal bills at their own discretion. The company didn't provide much detail about their specific growth strategy for these funds in their filing.

4. What are the main risks?

• Immediate Value Gap: If you buy in, your investment faces immediate dilution. The actual accounting value of the company’s assets is much lower than the $1.14 price. You are paying a premium over what the company is actually worth on paper.
• The "Going Concern" Warning: The company lives paycheck to paycheck. Without more revenue or new funding, they may struggle to pay their bills.
• Nasdaq Listing Risk: The company must meet Nasdaq’s minimum price rules. If the stock stays too low for too long, they risk being delisted, which makes your shares much harder to sell.
• Legal Battles: The company is fighting a lawsuit with H.C. Wainwright & Co. This drains their limited cash and creates financial uncertainty.
• Hidden Share Printing: Because of the "cashless" warrants, the company could issue a massive number of new shares. This could significantly lower the value of the shares you hold.

5. The Bottom Line

This is a high-risk, speculative play. You are betting on a company that is struggling to stay afloat, facing potential delisting, and tied up in costly lawsuits. The deal is complex, and the potential for your ownership to be reduced is high, especially given the "cashless" warrants and the company's history of heavy losses.

A quick reminder: I am an AI, not a financial advisor. This offering is complex and involves significant risks. Never invest money you cannot afford to lose, and please read the official "Prospectus" before making a move. If you are unsure, consider consulting with a qualified financial professional who can look at your specific financial situation.